Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors

Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechanism to explain why this mutation behaves differently from other KRAS mutations had long been...

Descripción completa

Detalles Bibliográficos
Autores principales: McFall, Thomas, Schomburg, Noah K., Rossman, Kent L., Stites, Edward C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643456/
https://www.ncbi.nlm.nih.gov/pubmed/33153459
http://dx.doi.org/10.1186/s12964-020-00645-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643456/
https://www.ncbi.nlm.nih.gov/pubmed/33153459
http://dx.doi.org/10.1186/s12964-020-00645-3

Ejemplares similares